Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05591131 | Genetic Testing in African Americans(GTM-I) | active not recruiting | N/A | 21 | Augusta UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06836219 | Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario(BeLIVE) | recruiting | — | 300 | Consorzio OncotechOTHER | 1 | Feb 20, 2025 |
| clinicaltrials |
| NCT06838429 | PARPi and Ovarian Cancer Survival | not yet recruiting | — | 6,000 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06082765 | Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood | recruiting | — | 10,000 | Zhongnan HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06832397 | Detection of Peritoneal Metastases by Diagnostic LAparoscopy in Patients With Locally Advanced Cervical Carcinoma(SOLAR) | not yet recruiting | — | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827353 | Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency(OVNI-B) | recruiting | — | 300 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06825455 | Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Peking UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03449264 | Development of Clinical and Biological Database(BCBInstitut) | recruiting | N/A | 4,000 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04282356 | Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer(INTENS-IP) | recruiting | Phase 2 | 55 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05857397 | A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America(CONOR) | active not recruiting | — | 64 | Latin American Cooperative Oncology GroupOTHER | 2 | Feb 12, 2025 | clinicaltrials |
| NCT06084195 | Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging(MR-O-MICS) | recruiting | N/A | 120 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06822582 | Pelvic Health Rehabilitation After Breast and Gynecologic Cancer(GYVE) | recruiting | N/A | 20 | Laval UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05737303 | Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | recruiting | Phase 3 | 538 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT04057924 | Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN(SUIVICIN) | recruiting | — | 200 | University Hospital, BordeauxOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05200260 | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | recruiting | Phase 2 | 220 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06677242 | Serous Endometrial Intraepithelial Carcinoma (SEIC): Prospective Registration Study(SEIC) | not yet recruiting | — | 100 | Erasmus Medical CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06803381 | Somesthesia in Cancer Patients: Variability and Influence on Eating Experience(SOMEST'ALIM2) | not yet recruiting | — | 96 | Hospices Civils de LyonOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06489795 | German-funded Laparoscopic Approach to Cervical Cancer(G-LACC) | recruiting | N/A | 756 | Hannover Medical SchoolOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06805019 | Construction of a Model for the Differential Diagnosis of SArcoma/myoma Based on the RAdiomics Features: Single-center Observational Study(SARA) | recruiting | — | 176 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800391 | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients(REVERSE) | recruiting | Phase 2 | 31 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800612 | Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers | recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800677 | Methylated Biomarkers Predictive of Endometrial Cancer Risk(BioMEC) | active not recruiting | — | 200 | University of ManchesterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation(RAMP 201) | active not recruiting | Phase 2 | 225 | Verastem, Inc.INDUSTRY | 7 | Jan 29, 2025 | clinicaltrials |
| NCT04859530 | Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier | recruiting | N/A | 5,886 | Prof. Patrick PetignatOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04957511 | Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy | recruiting | — | 30 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06304610 | Hospital-based Validation of the New ELEVATE Screening Tool(ELEVATE-Pilot) | not yet recruiting | N/A | 200 | University Hospital, GhentOTHER | 2 | Jan 27, 2025 | clinicaltrials |
| NCT06793657 | Poppy Seed Use in Gastroenteric Fistula Diagnosis | active not recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06392997 | Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology(GynRNA) | recruiting | — | 2,500 | ZIWIGINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05909111 | MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos Therapy: Feasibility Study(Ethos Col) | recruiting | N/A | 15 | Recherche cliniqueOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06785077 | Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors | recruiting | N/A | 157 | European Institute of OncologyOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04846933 | Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC(DECIDER) | recruiting | N/A | 200 | Turku University HospitalOTHER_GOV | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06775470 | Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer | recruiting | — | 300 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06776055 | Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women | active not recruiting | — | 5,372 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06777082 | Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma(OVCAR) | recruiting | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06777147 | Reproductive Health Outcomes in Young Patients With Ovarian Cancer After Surgical Treatment: A Retrospective Study | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Jan 15, 2025 | clinicaltrials |
| NCT04061967 | Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer. | recruiting | N/A | 20,000 | Karolinska InstitutetOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774209 | Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 21, 2025source: clinicaltrials